HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IVL 984

structure in first source

Also Known As:

IVL-984; IVL984

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Barbellion, S: 1 article (04/2004)
2.	Brunel, P: 1 article (04/2004)
3.	Clark, R: 1 article (04/2004)
4.	Crofts, F: 1 article (04/2004)
5.	DeLise, B: 1 article (04/2004)
6.	Guittin, P: 1 article (04/2004)
7.	Hofmann, T: 1 article (04/2004)
8.	Lerman, S: 1 article (04/2004)
9.	Lockey, P: 1 article (04/2004)
10.	Nguyen, M: 1 article (04/2004)

Related Diseases

1.	Congenital Abnormalities (Deformity) 04/01/2004 - "Embryo-fetal studies of three VLA-4 antagonists, IVL745, IVL984, and HMR1031 [Crofts et al., Birth Defects Res B 71:55-68 (this issue), 2004] with exposure on gestation days (GD) 6-17 (rat), 6-18 (rabbit) or 6-15 (mouse) showed that only IVL984 treatment resulted in embryo lethality and cardiac defects. "

Related Drugs and Biologics

1.	Integrin alpha4beta1 (VLA-4)
2.	3- (N- (3,4- dimethoxybenzyl)- 2- (2- (3- methoxy- 4- (3- o- tolylureido)phenyl)acetylamino)acetamido)propanoic acid
3.	(3S)- 3- (((2S)- 2- (4,4- dimethyl- 3- (4- ((((2- methylphenyl)amino)carbonyl)amino)benzyl)- 2,5- dioxoimidazolidin- 1- yl)- 4- methylpentanoyl)amino)- 3- phenylpropanoic acid